Lithium Carbonate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lithium Carbonate: From Mood Stabilisation to Pseudoachondroplasia
One-Sentence Summary
Lithium carbonate (DrugBank DB14509) is pharmacologically known for its mood-stabilising effects via GSK3β/IMPase inhibition, though this evidence pack contains no formal record of its original approved indication. The TxGNN model’s top prediction is Pseudoachondroplasia, a rare skeletal dysplasia, but this is supported by 0 clinical trials and 0 publications — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (original_indications empty). Lithium is pharmacologically known for mood stabilisation, referenced only indirectly in the model’s own rationale text. |
| Predicted New Indication | Pseudoachondroplasia |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for lithium carbonate is not available in this evidence pack (flagged as a High-severity data gap). Based on the rationale supplied alongside the prediction, lithium is pharmacologically known to inhibit glycogen synthase kinase-3β (GSK3β) and inositol monophosphatase (IMPase), pathways linked to its established mood-stabilising effects.
Pseudoachondroplasia is caused by COMP gene mutations that lead to misfolded protein accumulation in the chondrocyte endoplasmic reticulum and subsequent chondrocyte apoptosis. The proposed link is that GSK3β inhibition activates Wnt/β-catenin signalling and autophagy, which in theory could influence chondrocyte survival.
However, this link is explicitly flagged as speculative even in the source rationale: there is no direct molecular or animal-model evidence that lithium affects clearance of misfolded COMP protein. The evidence pack itself notes the high TxGNN score more likely reflects the sparsity of connections around this rare-disease node in the knowledge graph (an embedding-level similarity) rather than a genuine pharmacological relationship.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
TFDA/PI warnings and contraindications for lithium carbonate could not be retrieved for this evidence pack — this is flagged as a Blocking data gap, meaning the safety profile cannot yet be assessed against the standard S1 safety screening stage. No drug interaction data was found (DDI query status: not found). Because the drug is not currently marketed in Australia (0 ARTG entries), no local Product Information exists to reference; safety data would need to be sourced from an approved overseas formulation before any further evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the TxGNN model score, with no clinical trials, literature, or mechanistic evidence specific to pseudoachondroplasia — and the source rationale itself cautions this is likely an artefact of sparse knowledge-graph connections around a rare-disease node rather than a real pharmacological signal. A Blocking safety data gap also prevents any preliminary safety assessment.
To proceed, the following is needed:
- TFDA/PI-sourced warnings, contraindications, and interaction data for lithium carbonate (currently Blocking)
- Confirmed mechanism-of-action data from DrugBank or primary literature
- Preclinical evidence (e.g., in vitro chondrocyte/COMP misfolding models) testing whether GSK3β inhibition affects pseudoachondroplasia-relevant pathology
- Given the complete absence of trial/literature evidence for this specific indication, this candidate is a poor use of limited review resources compared to alternatives in the same prediction set — notably rank 9 (WHIM syndrome, L4/S1, “Research Question”), which has a documented clinical basis (lithium’s known leukocytosis effect) and may warrant separate evaluation instead
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.